glp-1 agonist definition and Anesthesia: Considerations and Cautions for CRNAs Glucagon-like peptide-1 receptor: mechanisms and
Description
S1) (McGuinness and Higgins 2020)
193 Although some results have been achieved in animal models, clinical studies on GLP-1 RA remain limited
Clinical Evidence for GLP-1 Receptor Agonists in Alzheimers Disease. PubMed Cheng HW et al
Monotherapy vs
The mean follow-up on-treatment was 181 days (median 155 days, IQR 71 to 290 days) for tirzepatide initiators and 174 days (median 148 days, IQR 82 to 254 days) for semaglutide initiators
